International Clinical Trial: Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07445295) titled 'Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma' on Feb. 25.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Chipscreen Biosciences, Ltd.

Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Intervention: Drug: Chiauranib Drug: Toripalimab Injection Drug: Albumin-paclitaxel Injection Drug: Gemcitabine Injection Drug: Chiauranib placebo

Recruitment...